Akero Therapeutics Inc.

09/09/2024 | Press release | Distributed by Public on 09/09/2024 05:02

Akero Therapeutics Announces First Patient Dosed in Phase 3 SYNCHRONY Outcomes Study of Efruxifermin in Patients with Compensated Cirrhosis Due to MASH

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.